

**Current and Previous PGY2 Infectious Diseases Residents  
University of Colorado School of Pharmacy/UCHealth University of Colorado  
Hospital**

1. Dorie Hoody, Pharm.D., BCPS (Infectious Diseases Specialty Residency, 2001-2002): Senior Clinical Instructor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Formerly Clinical Specialist in Infectious Diseases & Drug Information Services, University of Colorado Hospital, Denver, CO.
  - Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC, Fish DN. Evaluation of levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. **Antimicrobial Agents and Chemotherapy** 2006; 50:1937-1945.
2. Colleen Wegzyn, Pharm.D. (Infectious Diseases Specialty Residency, 2002-2003): Clinical Science Manager, Abbott Nutrition, Denver, CO. Formerly Clinical Sciences Liaison for Infectious Diseases/HIV, Roche Pharmaceuticals, Denver, CO.
3. Deborah Anderson, Pharm.D., BCCCP (Infectious Diseases Specialty Residency, 2003-2004): Clinical Pharmacist in Infectious Diseases and Critical Care, Denver Health Medical Center, Denver, CO.
  - Anderson D, Fish DN, Hiltz A. An assessment of antipseudomonal antimicrobial usage: the impact of antimicrobial restrictions. 44th Annual Meeting of the American Society for Microbiology, Washington, DC. October, 2004. **Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy** 2004:753 (abstract C2-1985).
4. Joshua Schwiesow, Pharm.D., BCPS (Infectious Diseases Specialty Residency, 2004-2005): Clinical Specialist in Infectious Diseases, Kaiser Permanente of Colorado, Denver, CO. Formerly Clinical Pharmacist in Infectious Diseases, National Jewish Medical and Research Center, Denver, CO.
5. Joel Coon, Pharm.D., BCACP (Infectious Diseases Specialty Residency, 2005-2006): Staff Pharmacist, South Peninsula Hospital, Homer, AK.
6. Stephanie Kuhn, Pharm.D., BCPS AQ-ID (Infectious Diseases Resident, 2012-2013): Antimicrobial Stewardship Pharmacist, Wesley Medical Center, Wichita, KS.
  - Kuhn S, Winterland J, Goolsby T, Barron M, Barber G, Fish DN. Daptomycin: Increasing appropriateness and decreasing costs through antimicrobial stewardship interventions. 53<sup>rd</sup> Annual Meeting of the American Society for Microbiology, Denver, CO. September 10-13, 2013. **Abstracts of the 53<sup>rd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy** 2013: abstract K-1288.
  - Kuhn S, Goolsby T, Barron M, Barber G, Fish D. A Retrospective Analysis on the Impact of Pharmacist Interventions on Antimicrobial Stewardship. 16<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 9-12, 2013.

7. Matthew Miller, Pharm.D., BCPS AQ-ID (Infectious Diseases Resident, 2013-2014): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, Children's Hospital Colorado, Aurora, CO. Formerly Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UHealth/University of Colorado Hospital, Aurora, CO; and Clinical Specialist in Infectious Diseases/Emergency Medicine, Trinity Mother Frances Health System, Tyler, TX.
  - Miller MA, Fish DN, Goolsby TA, Barber GA, Mueller SW. Comparison of treatment outcomes and safety with nafcillin or cefazolin for the management of methicillin-sensitive *Staphylococcus aureus* bacteremia. 54<sup>th</sup> Annual Meeting of the American Society for Microbiology, Washington, DC. September 6-9, 2014. **Abstracts of the 54<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy 2014**: abstract L-405.
  - Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Mueller SW. Cefazolin versus Nafcillin for Methicillin-Susceptible *Staphylococcus aureus* Bloodstream Infections. **Journal of Microbiology, Immunology, and Infection** 2018; Aug 18. pii: S1684-1182(18)30304-9. doi: 10.1016/j.jmii.2018.07.006.
8. Amber Streifel, Pharm.D., BCPS (Infectious Diseases Resident, 2014-2015): Infectious Diseases/Antimicrobial Stewardship Pharmacist, Oregon Health & Science University, Portland, OR. Formerly Infectious Diseases/Antimicrobial Stewardship Pharmacist, St. Mary's Medical Center, Grand Junction, CO.
  - Streifel A, Schoeppler K, Zamora M, Fish DN. Treatment of Respiratory Syncytial Virus (RSV), Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV) with Ribavirin in Lung Transplant Recipients. ID Week 2015, San Diego, CA. October 7-11, 2015. **ID Week 2015 Abstracts 2015**: abstract 1196.
9. Alexander Novin, Pharm.D., BCPS, BCIDP (Infectious Diseases Resident, 2015-2016): Infectious Diseases/Antimicrobial Stewardship Pharmacist, UHealth/Memorial Medical Center, Colorado Springs, CO.
  - Novin AR, Miller MA, Perterson EL, Schoeppler KE, Barber GR, Mueller SW, McCollister BD, Fish D. Predictors of mortality associated with enterococcal bacteremia. 19<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 5-7, 2016.
10. Kelsey Melander, Pharm.D., BCIDP (Infectious Diseases Resident, 2016-2017): Antimicrobial Stewardship Clinical Pharmacist, Rose Medical Center, Denver, CO.
  - Melander K, Miller M, Fish D, Barber G, Bickel A, Weinberg A. Evaluation of the viral respiratory PCR panel on healthcare utilization. 20<sup>th</sup> Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 10-13, 2017.

11. Nichole Neville, Pharm.D., BCIDP (Infectious Diseases Resident, 2017-2018): Antimicrobial Stewardship Clinical Pharmacist, Swedish Medical Center, Englewood, CO.
- Neville NR, Yang ES, Wong FH, Miller MA, Barber GR, Kaiser JN, Tobin JK, Gutman JA. Evaluation of an Oral Ribavirin Protocol for Treating Community Acquired Respiratory Virus (CARV) Infections in Patients with Hematologic Malignancy. 21st Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 9-12, 2018.
  - Morrisette T, Neville N, Britton A, Mueller SW, Jacknin G, Miller MA, Fish DN. Pharmacokinetic and pharmacodynamics evaluation of cefepime in overweight and obese patients. ID Week 2019, Washington DC. October 3-6, 2019. **ID Week 2019 Abstracts** 2019: abstract 1535.
12. Taylor Morrisette, Pharm.D (Infectious Diseases Resident, 2018-2019): Assistant Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC. Formerly Postdoctoral Research Fellow in Health Outcomes and Pharmacokinetics/Pharmacodynamics, Wayne State University, Detroit, MI.
- Morrisette T, Van Matre A, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber G, Chase S, Tobin J, Fish DN, Gutman JA, Oral Vancomycin Prophylaxis as Secondary Prevention for *Clostridioides difficile* Infection in the Hematopoietic Stem Cell Transplant and Hematologic Malignancy Population. **Biology of Blood and Marrow Transplantation** 2019; doi.org/10.1016/j.bbmt.2019.06.021.
  - Morrisette T, Neville N, Britton A, Mueller SW, Jacknin G, Miller MA, Fish DN. Pharmacokinetic and pharmacodynamics evaluation of cefepime in overweight and obese patients. ID Week 2019, Washington DC. October 3-6, 2019. **ID Week 2019 Abstracts** 2019: abstract 1535.
  - Morrisette T, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-world use of tedizolid phosphate: a case series of long-term tolerability. ID Week 2019, Washington DC. October 3-6, 2019. **ID Week 2019 Abstracts** 2019: abstract 2285.
  - Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. **Open Forum Infectious Diseases** 2022; May 23;9(6):ofac028. doi: 10.1093/ofid/ofac028. eCollection 2022 Jun. PMID: 35615295.
13. Kyle Molina, Pharm.D. (Infectious Diseases Resident, 2019-2020): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, Scripps Memorial Hospital, La Jolla, CA. Formerly Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UCHealth/University of Colorado Hospital, Aurora, CO.
- Molina KC, Morrisette T, Miller MA, Huang V, Fish DN. The Emerging Role of  $\beta$ -lactams in the Treatment of Methicillin-Resistant *Staphylococcus aureus* Blood Stream Infections. **Antimicrobial Agents and Chemotherapy**. 2020 Jun; 64(7):e00468-20. Editor's Pick Distinction.
  - Krsak M, Morrisette T, Miller MA, Molina KC, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment for Serious Gram-positive Infections with Long-acting Lipoglycopeptides: A Review. **Pharmacotherapy**. 2020 May;40(5):469-478.

- Boyle E, Dorgan E, Lunowa C, Molina KC, Johnson T, Miller MA, Huang M, Fish DN. External Validation of the Methicillin-Resistant *Staphylococcus aureus* Bacteremia Score. **IDWeek 2020 abstracts.**
  - Ngo N, Sielatchom-Noubissie L, Molina KC, Johnson T, Huang M, Hojat L, Kiser T, Miller MA. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections. **IDWeek 2020 abstracts.**
  - Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. **Open Forum Infectious Diseases** 2022; May 23;9(6):ofac028. doi: 10.1093/ofid/ofac028. eCollection 2022 Jun. PMID: 35615295.
14. Tanner Johnson, Pharm.D. (Infectious Diseases Resident, 2020-2021): Antimicrobial Stewardship Pharmacist, Mayo Clinic, Rochester, MN.
- Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of bezlotoxumab for prevention of recurrent *Clostridioides difficile* infection among transplant recipients. *Open Forum Infectious Diseases*; 2021 Jun 4;8(7):ofab294.
  - Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant *Staphylococcus aureus* bacteraemia compared with standard of care. *International Journal of Antimicrobial Agents* 2021; Apr;57(4):106310.
  - Boyle E, Dorgan E, Lunowa C, Molina K, Johnson T, Miller M, Huang M, Fish D. External Validation of the Methicillin-Resistant *Staphylococcus aureus* Bacteremia Score. **IDWeek 2020 abstracts.**
15. Williams Monier Texidor, Pharm.D. (Infectious Diseases Resident, 2021-2022): Oncology Pharmacist, Miami Cancer Institute/Baptist Health South Florida, Miami, FL

Projects:

- Monier Texidor W, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, Storer M, Fish DN. Oritavancin as Sequential Therapy in Gram-Positive Bloodstream Infections. **BMC Infectious Diseases** 2024; 24:127. doi.org/10.1186/s12879-023-08725-8.
- Evaluation of daptomycin or linezolid monotherapy vs. combination therapy of daptomycin + a beta-lactam for VRE infections.
- Development and implementation of a protocol for empiric dose adjustment of antimicrobials in patients with augmented renal clearance

16. Madison Salam, Pharm.D. (Infectious Diseases Resident, 2022-2023): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UCHealth University of Colorado Hospital, Aurora, CO.

Projects:

- Salam ME, Molina K, Miller M, Jeffres M, Huang M, Fish DN. Evaluation of Oral Amoxicillin/Clavulanate for Urinary Tract Infections Caused by Ceftriaxone Non-Susceptible Enterobacterales. **Pharmacy** 2024; 12:60. https://doi.org/10.3390/pharmacy12020060.

- Salam ME, Miller MA, Molina KC, Huang M, Jeffres MN, Fish DN. Three-arm comparison of fidaxomicin monotherapy, fidaxomicin plus bezlotoxumab, and vancomycin plus bezlotoxumab on 90-day *C. difficile* clinical success. 34th European Congress on Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 20-23, 2024. **34<sup>th</sup> ECCMID Abstracts 2024**; abstract 7300.

17. Blake Jennewein, Pharm.D. (Infectious Diseases Resident, 2023-2024): Clinical Pharmacist in Infectious Diseases/Antimicrobial Stewardship, Carilion Roanoke Memorial Hospital, Roanoke, VA.

Projects:

- Institutional effectiveness and stewardship implications of changing from vancomycin to linezolid/daptomycin as empiric therapy of MRSA infections
- Antimicrobial prophylaxis during chest tube placement in lung transplant patients

18. Eugenio Hernandez, Pharm.D. (Infectious Diseases Resident, 2024-2025): Clinical Pharmacist in Infectious Diseases/Antimicrobial Stewardship, Intermountain Health, Salt Lake City, UT.

Projects:

- Institutional effectiveness and antimicrobial stewardship implications of implementation of PCR testing for rapid identification of MRSA infections
- Real-world experience with maribavir for treatment of CMV infection in high-risk transplant patients

19. Rebecca O'Toole, Pharm.D.: Infectious Diseases Resident, 2025-2026:

Projects:

- Oral antibiotics for management of pyelonephritis in kidney transplant recipients: a retrospective cohort study
- *Clostridioides difficile* prophylaxis in high-risk patients: impact of implementation of Epic practice alerts on prevention of recurrent infections